Roflumirast is a respiratory-health medication classified as a phosphodiesterase-4 (PDE4) inhibitor. It is available as a single-strength pill containing 500 mg of the active ingredient roflumirast. In Hong Kong, roflumirast is a prescription-only product regulated by the Hong Kong Department of Health, Medicines Division. The drug is marketed under a variety of generic names and may appear in different branding depending on the manufacturer.
Roflumirast belongs to the class of PDE4 inhibitors. PDE4 is an enzyme that breaks down cyclic adenosine monophosphate (cAMP) inside inflammatory cells of the airways. By blocking PDE4, roflumirast raises intracellular cAMP levels, which leads to:
These actions collectively help improve lung function and reduce the frequency of exacerbations in chronic respiratory conditions. The onset of anti-inflammatory effect typically occurs within days, with the full therapeutic benefit developing over several weeks of daily use. Roflumirast is administered orally, and its bioavailability is high; it is metabolised primarily by the liver via the CYP3A4 pathway and excreted in the urine and feces.
Roflumirast is approved in Hong Kong for the maintenance treatment of severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis. It is intended for patients who experience frequent exacerbations despite standard inhaled therapies (such as long-acting bronchodilators). The medication is not a rescue inhaler; rather, it is used on a long-term basis to lessen the inflammatory component of COPD.
Typical patients who may benefit include adults with:
Roflumirast does not replace bronchodilator or inhaled corticosteroid treatment; it is an add-on therapy aimed at further reducing exacerbation risk.
These effects are usually mild to moderate and often improve with continued therapy or dose titration.
Patients should provide a complete medication list-including over-the-counter drugs, supplements, and herbal products-to their healthcare provider before initiating roflumirast.
If any concerning laboratory abnormalities or clinical symptoms arise, timely communication with the prescribing clinician is essential.
This article provides educational information about roflumirast and is not a substitute for professional medical advice. Treatment decisions, including the use of unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Roflumirast is supplied as a single-strength oral pill containing 500 mg of the active ingredient. The tablet is typically white to off-white and may have a scored line for easy handling, though it is not intended to be split.
Roflumirast is approved specifically for severe COPD with chronic bronchitis. Its use in asthma is not endorsed by regulatory agencies in Hong Kong and should only be considered within a clinical trial or under specialist supervision.
Roflumirast is not classified as a prohibited substance by most occupational or sports drug-testing programs. However, athletes should verify with their governing bodies, as policies may change.
Unlike inhaled corticosteroids, which act locally in the lungs, roflumirast works systemically by inhibiting an enzyme that reduces airway inflammation. It is used as an add-on therapy when inhaled treatments alone are insufficient.
If nausea becomes persistent or severe, contact your healthcare provider. They may advise taking the medication with food, adjusting the dose, or prescribing an anti-emetic.
Strong CYP3A4 inhibitors such as certain antifungals (e.g., ketoconazole) can increase roflumirast levels and heighten side-effect risk. Discuss any antifungal therapy with your prescriber before combining them.
Yes, but keep the medication in its original packaging with a copy of the prescription. Some countries may require additional documentation for prescription drugs, so check local regulations before travel.
Current evidence does not indicate a direct effect on glucose metabolism, but patients with diabetes should monitor their blood sugar regularly, as systemic inflammation changes can influence control.
The leading reasons include intolerable gastrointestinal side effects, significant weight loss, or emergence of depressive symptoms. Any decision to stop should be made together with a healthcare professional.
